Home Dust Mites Promote MUC5AC Hyper-Expression by Modulating the sNASP/TRAF6 Axis in the Airway Epithelium

Ming-Zhen Chen1, Shao-An Wang1, Shih-Chang Hsu2,3

  • 1School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.

Insights

House dust mites trigger asthma by activating Toll-like receptors (TLR), leading to mucus overproduction. A new study reveals the somatic nuclear autoantigenic sperm protein (sNASP)/TRAF6 pathway regulates this response, offering a potential therapeutic target.

Area of Science:

  • Immunology
  • Molecular Biology
  • Respiratory Medicine

Background:

  • House dust mites (HDMs) are major respiratory allergens linked to allergic asthma.
  • Innate immunity, particularly Toll-like receptors (TLRs), plays a crucial role in HDM-induced airway inflammation and mucus production.

Purpose of the Study:

  • To investigate the signaling mechanisms of HDM extract in activating TLRs, leading to mucus hypersecretion and airway inflammation.
  • To elucidate the role of the somatic nuclear autoantigenic sperm protein (sNASP)/tumor necrosis factor receptor-associated factor 6 (TRAF6) axis in HDM-induced asthma.

Main Methods:

  • Investigated HDM extract's effect on Mucin 5AC (MUC5AC) biogenesis in bronchial epithelial cells via TLR2/4 signaling.
  • Examined the interaction between sNASP and TRAF6, and downstream signaling pathways (p38 MAPK, NF-κB).
  • Utilized a mouse model of HDM-induced asthma and tested a TRAF6-blocking peptide (PEP-NASP).

Main Results:

  • HDM extract stimulated MUC5AC biogenesis through the TLR2/4/MyD88/TRAF6 pathway.
  • sNASP normally inhibits TRAF6 activation; HDM stimulation phosphorylates sNASP, activating TRAF6 and downstream pathways.
  • NASP-knockdown exacerbated TRAF6 signaling and MUC5AC production.
  • HDM-induced asthma model showed increased airway hyperresponsiveness, MUC5AC, IgE, IL-5, and IL-13.
  • PEP-NASP treatment ameliorated HDM-induced asthma symptoms in mice.

Conclusions:

  • The sNASP/TRAF6 axis is a key regulator of HDM-induced mucus overproduction and airway inflammation in asthma.
  • Targeting the sNASP/TRAF6 interaction with peptides like PEP-NASP shows therapeutic potential for allergic asthma treatment.

Related Concept Videos

Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.8K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
547
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
413